Kindred Biosciences (KIN) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Kindred Biosciences (KIN) PT Raised to $16 at H.C. Wainwright
August 13, 2018 12:14 PM EDTH.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Kindred Biosciences (NASDAQ: KIN) to $16.00 (from $12.00) while maintaining a Buy rating.
Ramakanth said initial signs show a good appetite for Mirataz.
... More